Antithrombin III for critically ill patients

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2008, Pages

  Afshari, Arash ^a   Wetterslev, Jørn ^b   Brok, Jesper ^c   Møller, Ann Merete ^d  

^a University of Copenhagen   (Denmark)

^b Centre for Clinical Intervention Research ^*  (Denmark)

^c Mental Health Center Glostrup   (Denmark)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTIHYPERTENSIVE AGENT; ANTITHROMBIN III; BARBITURIC ACID DERIVATIVE; CLONIDINE; DEFIBROTIDE; DEXTRAN 70; DIHYDROERGOTAMINE; DOBUTAMINE; DOPAMINE; GABAXATE MESILATE; HEPARIN; HEPARIN CALCIUM; HYDRALAZINE; INOTROPIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; MAGNESIUM SULFATE; MANNITOL; NORADRENALIN; PHENYTOIN; PLACEBO; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTITHROMBIN DEFICIENCY; ANURIA; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; ECLAMPSIA; EVENING DOSAGE; GYNECOLOGIC DISEASE; HEART INFARCTION; HUMAN; INJURY; INTENSIVE CARE UNIT; LENGTH OF STAY; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LIVER TOXICITY; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG EMBOLISM; META ANALYSIS; MONOTHERAPY; MORTALITY; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; PERITONITIS; PREECLAMPSIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SENSITIVITY ANALYSIS; SEPSIS; SEPTIC SHOCK; SINGLE DRUG DOSE; SURVIVAL; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOSIS; TRAUMATIC BRAIN INJURY; VEIN OCCLUSION; VEIN THROMBOSIS;

EID: 55049104856     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005370.pub2     Document Type: Review

References (88)

1. Albert 1992 {published data only} * Albert J, Blomqvist H, Gardlund B, Jakobsson J, Svensson J, Blomback M. Effect of antithrombin concentrate on haemostatic variables in critically ill patients. Acta Anaesthesiologica Scandinavia 1992;36: 745-52. [MEDLINE: 1466208]
2. Baudo 1992 {published data only} * Baudo F, DeGasperi A, de Cataldo F, Caimi TM, Cattaneo D, Redaelli R, et al.Antithrombin III supplementation during orthotopic liver transplantation in cirrhotic patients: A randomized trial. Thrombosis Research 1992;68:409-16. [MEDLINE: 1290169]
3. Baudo 1998 {published data only} * Baudo F, Caimi TM, de Cataldo F, Ravizza A, Arlati S, Casella G, et al.Antithrombin III (ATIII) replacement therapy in patients with severe sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Medicine 1998; 24:336-42. [MEDLINE: 9609411]
4. Diaz-Cremades 1994 {published data only} * Diaz-Cremades JM, Lorenzo R, Sanchez M, Moreno MJ, Alsar MJ, Bosch JM, et al.Use of antithrombin III in critical patients. Intensive Care Medicine 1994;20:577-80. [MEDLINE: 7706571]
5. Eisele 1998 {published data only} * Eisele B, Lamy M, Thijs LG, Keinecke HO, Schuster HP, Matthias FR, et al.Antithrombin III in patients with severe sepsis. Intensive Care Medicine 1998;24:663- 72. [MEDLINE: 9722035]
6. Fourrier 1993 {published data only} * Fourrier F, Chopin C, Huart JJ, Runge I, Caron C, Goudemand J. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 1993;104:882-8. [MEDLINE: 8365305]
7. Fulia 2003 {published data only} * Fulia F, Cordaro S, Meo P, Gitto P, Gitto E, Trimarchi G, et al.Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants. Biology of the Neonate 2003;83: 1-5. [MEDLINE: 12566675]
8. Grenander 2001 {published data only} * Grenander A, Bredbacka S, Rydvall A, Aroch R, Edner G, Koskinen LO, et al.Antithrombin treatment in patients with traumatic brain Injury; a pilot study. Journal of Neurosurgical Anesthesiology 2001;13 (1):49-56. [MEDLINE: 11145479]
9. Haire 1998 {published data only} * Haire WD, Ruby EI, Stephens LC, Reed E, Tarantolo SR, Pavletic ZS, et al.A prospective randomized double-blind trial of antithrombin III concentrate in the treatment of multiple-organ dysfunction syndrome during hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation 1998;4:142-50. [MEDLINE: 9923412]
10. Harper 1991 {published data only} * Harper PL, Williamson L, Park G, Smith JK, Carrell RW. A pilot study of antithrombin replacement in intensive care management: the effects on mortality, coagulation and renal function. Transfusion Medicine 1991;1:121-8. [MEDLINE: 9259838]
11. Inthorn 1997 {published data only} * Inthorn D, Hoffmann JN, Hartl WH, Muhlbayer D, Jochum M. Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock 1997;8:328-34. [MEDLINE: 9361342]
12. Kobayashi 2003 {published data only} * Kobayashi T, Terao T, Ikenoue T, Sameshima H, Nakabayashi M, Kajiwara Y, et al.BI 51 017 Study Group. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Seminars in Thrombosis and Hemostasis 2003; 29:645-52. [MEDLINE: 14719181]
13. Langely 1993 {published data only} * Langley PG, Hughes RD, Forbes A, Keays R, Williams R. Controlled trial of antithrombin III supplementation in fulminant hepatic failure. Journal of Hepatology 1993;17(3):326-31. [MEDLINE: 8315261]
14. Maki 2000 {published data only} * Maki M, Kobayashi T, Terao T, Ikenoue T, Satoh K, Nakabayashi M, et al.BI51.017 Study Group. Antithrombin therapy for severe preeclampsia: results of a double-blind, randomized, placebo-controlled trial. Thrombosis and Haemostasis 2000;84(4):583-90. [MEDLINE: 11057854]
15. Mitchell 2003 {published data only} * Mitchell L, Andrew M, Hanna K, Abshire T, Halton J, Wu J, et al.Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thrombosis and Haemostasis 2003;90:235-44. [MEDLINE: 12888870]
16. Schmidt 1998 {published data only} * Schmidt B, Gillie P, Mitchell L, Andrew M, Caco C, Roberts R. A placebo-controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine 1998;158:470-6. [MEDLINE: 9700123]
17. Schorr 2000 {published data only} * Schorr M, Siebeck M, Zugel N, Welcker K, Gippner-Steppert C, Czwienzek E, et al.Antithrombin III and local serum application: adjuvant therapy in peritonitis. European Journal of Clinical Investigation 2000;30(4):359-66. [MEDLINE: 10759886]
18. Smith-Erichsen 1996 {published data only} * Smith-Erichsen N, Aasen AO, Kongsgaard UE, Bakka A, Bergen A, Bjerkelund CE, et al.The effect of antithrombin III substitution therapy on components of the plasma protease systems in surgical patients. Clinical Intensive Care 1996;7:291-6.
19. Warren 2001 {published data only} Rublee D, Opal SM, Schramm W, Keinecke HO, Knaub S. Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Critical Care 2002;6:349-56. [MEDLINE: 12225612]
20. * Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, et al.Caring for the critically ill patient. High-dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA 2001;286(15):1869-78. [MEDLINE: 11597289]
21. Waydhas 1998 {published data only} * Waydhas C, Nast-Kolb D, Gippner-Steppert C, Trupka A, Pfundstein C, Schweiberer L, et al.High-dose antithrombin III treatment of severely injured patients: results of a prospective study. The Journal of Trauma, Injury, Infection and Critical Care 1998;45(5):931-40. [MEDLINE: 9820705]
22. Balk 1995 {published data only} * Balk RA, Bedrosian C, McCormick L, Baughman J, Eisele B, Keinecke HO, et al.Prospective double blind placebo-controlled trial of ATIII substitution in sepsis. Intensive Care Medicine 1995;21 Suppl 1:17.
23. Banfi 1996 {published data only} * Banfi R, Borselli G, Giannelli P, Marinai C, Ruffino I. Antithrombin III use in intensive care units. Journal of Applied Therapeutics 1996;1 (2):179-83.
24. Blauhut 1985 {published data only} * Blauhut B, Kramar H, Vinazzer H, Bergmann H. Substitution of antithrombin III in shock and DIC: a randomized study. Thrombosis Research 1985;39:81-9. [MEDLINE: 4035650]
25. Brangenberg 1997 {published data only} * Brangenberg R, Bodensohn M, Burger U. Antithrombin-III substitution in preterm infants - effect on intracranial hemorrhage and coagulation parameters. Biology of the Neonate 1997;72(2):76-83. [MEDLINE: 9267673]
26. Danielsson 1997 {published data only} * Danielsson P, Nilsson L, Nettelblad H, Sjoberg F. Is there a need for antithrombin III substitution early after burn injury?. Burns 1997; 23(4):300-5. [MEDLINE: 9248638]
27. du Cheyron 2006 {published data only} * du Cheyron D, Bouchet B, Bruel C, Daubin C, Ramakers M, Charbonneau P. Antithrombin supplementation for anticoagulation during continuous hemofiltration in critically ill patients with septic shock: a case-control study. Critical Care 2006;10(2):R45. [MEDLINE: 16542495]
28. Fertmann 2006 {published data only} * Fertmann JM, Wimmer CD, Arbogast HP, Illner WD, Tarabichi A, Calasan I, et al.Single-shot antithrombin in human pancreas-kidney transplantation: reduction of reperfusion pancreatitis and prevention of graft thrombosis. Transplant International 2006;19(6):458-65. [MEDLINE: 16771866]
29. Fourrier 1990 {published data only} * Fourrier F, Lestavel P, Chopin C, Marey A, Goudemand J, Rime A. Meningococcemia and purpura fulminans in adults: acute deficiencies of protein C and S and early treatment with antithrombin III concentrates. Intensive Care Medicine 1989;16:121-4. [MEDLINE: 2139671]
30. Hanada 1985 {published data only} * Hanada T, Abe T, Takita H. Antithrombin III concentrates for treatment of disseminated intravascular coagulation in children. American Journal of Pediatric Hematology/Oncology 1985;7(1):3-8. [MEDLINE: 4037242]
31. Haussmann 2006 {published data only} * Haussmann U, Fischer J, Eber S, Scherer F, Seger R, Gungor T. Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy. Haematologica 2006;91(6):795-800. [MEDLINE: 16769582]
32. Hellgren 1984 {published data only} * Hellgren M, Javelin L, Hagnevik K, Blomback M. Antithrombin III concentrate as adjuvant in DIC treatment. A pilot study in 9 severely ill patients. Thrombosis Research 1984;35(4):459-66.
33. Hoffmann 2004 {published data only} Hoffmann JN, Mühlbayer D, Jochum M, Inthorn D. Effect of long-term and high-dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Critical Care Medicine 2004;32(9):1851-9. [MEDLINE: 15343012]
34. Hoffmann 2006 {published data only} Hoffmann JN, Wiedermann CJ, Juers M, Ostermann H, Kienast J, Briegel J, et al.Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thrombosis and Haemostasis 2006;95(5):850-6. [MEDLINE: 16676077]
35. Ilias 2000 {published data only} * Ilias W, List W, Decruyenaere J, Lignian H, Knaub S, Schindel F, et al.Antithrombin III in patients with severe sepsis: a pharmacokinetic study. Intensive Care Medicine 2000;26(6):704-15. [MEDLINE: 10945387]
36. Inthorn 1998 {published data only} Inthorn D, Hoffmann JN, Hartl WH, Muhlbayer D, Jochum M. Effect of Antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock 1998;10(2):90-6. [MEDLINE: 9721974]
37. Jochum 1995 {published and unpublished data} * Jochum M. Influence of high-dose antithrombin concentrate therapy on the release of cellular proteinases, cytokines, and soluble adhesion molecules in acute inflammation. Seminars in Hematology 1995; 32 Suppl 2(4):19-32. [MEDLINE: 8821206]
38. Kienast 2006 {published data only} Kienast J, Juers M, Wiedermann CJ, Hoffmann JN, Ostermann H, Strauss R, et al.Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis 2006;4(1):90-7. [MEDLINE: 16409457]
39. Korninger 1987 {published data only} * Korninger C, Klepteko W, Miholic J, Schwarz C, Lechner K. Randomized trial of antithrombin-III versus placebo in patients undergoing peritoneo-venous shunt operation. Thrombosis And Haemostasis 1987;58(1):426.
40. Kowal-Vern 2000 {published data only} * Kowal-Vern A, McGill V, Walenga JM, Gamelli RL. Antithrombin (H) concentrate infusions are safe and effective in patients with thermal injuries. The Journal of Burn Care & Rehabilitation 2000;21: 115-27. [MEDLINE: 10752744]
41. Leitner 2006 {published data only} * Leitner JM, Firbas C, Mayr FB, Reiter RA, Steinlechner B, Jilma B. Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia. Clinical Pharmacology and Therapeutics 2006;79(1):23- 34. [MEDLINE: 16413239]
42. Maki 1987 {published data only} * Maki M, Terao T, Ikenoue T, Takemura T, Sekiba K, Shirakawa K, et al.Clinical evaluation of antithrombin III concentrate (BI 6.013) for disseminated intravascular coagulation in obstetrics. Well-controlled multicenter trial. Gynecology and Obstetric Investigation 1987; 23:230-40. [MEDLINE: 3111953]
43. Messori 2002 {published data only} * Messori A, Vacca F, Vaiani M, Trippoli S, Gruppo di Studio sull'antitrombina III. Antithrombin III in patients admitted to intensive care units: a multicenter observational study. Critical Care 2002;6(5):447-51. [MEDLINE: 12398786]
44. Mitchell 2003b {published data only} Mitchell LG, Andrew M, Hanna K, Abshire T, Halton J, Anderson R, et al.A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase - Results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study. Cancer 2003;97(2):508-16. [MEDLINE: 12518376]
45. Moriss 1997 {published data only} * Morris JD, Harris RE, Hashmi R, Sambrano JE, Gruppo RA, Becker AT. Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation. Bone Marrow Transplantation 1997;20(10):871-8. [MEDLINE: 9404929]
46. Muntean 1989 {published data only} * Muntean W, Rossegger H. Antithrombin III concentrate in preterm infants with IRDS: an open, controlled, randomized clinical trial (abstract). Thrombosis and Haemostasis 1989;62:288.
47. Nishiyama 2006 {published data only} Nishiyama T. Antithrombin can modulate coagulation, cytokine production, and expression of adhesion molecules in abdominal aortic aneurysm repair surgery. Anesthesia and Analgesia 2006;102(4): 1007-11. [MEDLINE: 16551889]
48. Palareti 1995 {published data only} * Palareti G, Legnani C, Coccheri S, Ridolfi L, Baudo F, Caimi TM, et al.Laboratory effects of antithrombin-III (ATIII) replacement in patients with sepsis and or postsurgical complications requiring hemodynamic and or respiratory support - A controlled, double-blind, randomized multicenter study. Thrombosis and Haemostasis 1995;73(6):1251.
49. Paternoster 2000 {published data only} * Paternoster DM, De Fusco D, Tambuscio B. Treatment with antithrombin III (AT III) concentrate in pre-eclampsia. International Journal of Gynaecology and Obstetrics 2000;71:175-6. [MEDLINE: 11064016]
50. Paternoster 2004 {published data only} * Paternoster DM, Fantinato S, Manganelli F. Efficacy of AT in preeclampsia: a case-control prospective trial. Thrombosis and Haemostasis 2004;91(2):283-9. [MEDLINE: 14961155]
51. Scherer 1994 {published data only} Scherer R, Gille A, Erhard J, Paar D, Kox WJ. The effect of substitution with antithrombin III and prothrombin complex (PPSB) concentrates in patients with end-stage liver disease. Anaesthesist 1994; 43(3):178-82. [MEDLINE: 8179167]
52. Scherer 1997 {published data only} * Scherer R, Kabatnik M, Erhard J, Peters J. The influence of antithrombin III (AT III) substitution to supranormal activities on systemic procoagulant turnover in patients with end-stage chronic liver disease. Intensive Care Medicine 1997;23:1150-8. [MEDLINE: 9434921]
53. Schuster 1997 {published data only} * Schuster HP, Eisele B, Keinecke HO, Heinrichs H, Mescheder A, Knaub S. S-AT III study: antithrombin III in patients with sepsis. Intensive Care Medicine 1997;23 Suppl 1:76.
54. Seitz 1989 {published data only} * Wolf M, Egbring R, Havemann K. The disturbance of hemostasis in septic shock: role of neutrophil elastase and thrombin, effects of antithrombin III and plasma substitution. European Journal of Haematology 1989;43:22-8. [MEDLINE: 2788582]
55. Shimada 1994 {published data only} * Shimada M, Matsumata T, Kamakura T, Hayashi H, Urata K, Sugimachi K. Modulation of coagulation and fibrinolysis in hepatic resection: a randomized prospective control study using antithrombin III concentrates. Thrombosis Research 1994;74(2):105-14. [MEDLINE: 8029811]
56. Terao 1989 {published data only} * Terao T, Kobayashi T, Imai N, Oda H, Karasawa T. Pathological state of the coagulatory and fibrinolytic system in preeclampsia and the possibility of its treatment. Asia-Oceania Journal of Obstetrics and Gynaecology 1988;15(1):25- 32. [MEDLINE: 2735838]
57. van Beek 1994 {published data only} * van Beek EJ, von der Mohlen MA, ten Cate JW, Brandjes DP, Buller HR. Antithrombin III concentrate in the treatment of DIC: a retrospective follow-up study. The Netherlands Journal of Medicine 1994;45(5):206-10. [MEDLINE: 7830846]
58. van Leeuwen 2003 {published data only} * van Leeuwen HJ, Heezius EC, Dallinga GM, van Strijp JA, Verhoef J, van Kessel KP. Lipoprotein metabolism in patients with severe sepsis. Critical Care Medicine 2003;31(5):1359-66. [MEDLINE: 12771603]
59. Vinazzer 1995 {published data only} * Vinazzer HA. Antithrombin III in shock and disseminate intravascular coagulation. Clinical and Applied Thrombosis/Hemostasis 1995; 1(1):62-5.
60. Von Kries 1985 {published data only} * Von Kries R, Stannigel H, Göbel U. Anticoagulant therapy by continuous heparin-antithrombin III infusion in newborns with disseminated intravascular coagulation. European Journal of Pediatrics 1985; 144:191-4. [MEDLINE: 4043133]
61. Wiedermann 2006 {published data only} Wiedermann CJ, Hoffmann JN, Juers M, Ostermann H, Kienast J, Briegel J, et al.High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine 2006;34(2):285-92. [MEDLINE: 16424704]
62. D'angelo 2005 {published data only} EPAS (Early Preeclampsia Antithrombin Study). Ongoing study December 2004.
63. Altman 2003 Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003;326(7382):219. [MEDLINE: 12543843]
64. Angus 2001 Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Critical Care Medicine 2001;29(7):1303-10. [MEDLINE: 11445675]
65. Becker 2000 Becker BF, Heindl B, Kupatt C, Zahler S. Endothelial function and hemostasis. Zeitschrift fur Kardiologie 2000;89(3): 160-7. [MEDLINE: 10798271]
66. Bernard 2001 Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al.Efficacy and safety of recombinant human activated protein C for severe sepsis. The New England Journal of Medicine 2001;344(10):699-709. [MEDLINE: 11236773]
67. Deveraux 2005 Devereaux PJ, Beattie WS, Choi PT, Badner NH, Guyatt GH, Villar JC, et al.How strong is the evidence for the use of perioperative beta blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trials. BMJ 2005;331(7512):313-21.
68. Egger 1997 Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34. [MEDLINE: 9310563]
69. Fourrier 2000 Fourrier F, Jourdain M, Tournoys A. Clinical trial results with antithrombin III in sepsis. Critical Care Medicine 2000;28 Suppl 9: 38-43. [MEDLINE: 11007196]
70. Gotzsche 2000 Gotzsche PC. Why we need a broad perspective on meta-analysis. It may be crucially important for patients. BMJ 2000;321(7261): 585-6. [MEDLINE: 10977820]
71. Higgins 2002 Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;15(11):1539-58. [MEDLINE: 12111919]
72. Higgins 2005 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd.
73. Lan 1983 Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70(3):659-63.
74. Larsson 2001 Larsson H, Åkerud P, Nordling K, Raub-Segall E, Claesson-Welsh L, Bjork I. A novel anti-angiogenic form of antithrombin with retained proteinase binding ability and heparin affinity. The Journal of Biological Chemistry 2001;276(15):11996-2002. [MEDLINE: 11278631]
75. Levi 2004 Levi M, de Jonge E, van der Poll T. New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology. Annals of Medicine 2004;36:41-9.
76. Müllner 2004 Müllner M, Urbanek B, Havel C, Losert H, Waechter F, Gamper G. Vasopressors for shock. Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI: DOI: 10.1002/14651858.CD003709.pub2]
77. Opal 2002 Opal SM, Kessler CM, Roemisch J, Knaub S. Antithrombin, heparin, and heparan sulfate. Critical Care Medicine 2002;30 Suppl 5:325-31. [MEDLINE: 12004255]
78. Opal 2003 Opal SM. Clinical trial design and outcomes in patients with severe sepsis. Shock 2003;Oct;20(4):295-302. [MEDLINE: 14501941]
79. Periti 2000 Periti P.Current treatment of sepsis and endotoxaemia. Expert opinion of Pharmacotherapy 2000;1(6):1203-17. [MEDLINE: 11249488]
80. Pogue 1997 Pogue JM, Yusuf S. Cumulating evidence from randomized trials: Utilizing sequential monitoring boundaries for cumulative meta-analysis. Controlled Clinical Trials 1997;18:580-93.
81. Pogue 1998 Pogue J, Yusuf S. Overcoming the limitations of current meta-analysis of randomised controlled trials. Lancet 1998;351(9095):47-52.
82. Polderman 2004 Polderman KH, Girbes ARJ. Drug intervention trials in sepsis: divergent results. Lancet 2004;363:1721-3. [MEDLINE: 15158636]
83. RevMan 5.0 The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan) Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
84. Rublee 2003 Rublee D, Opal SM, Schramm W, Keinecke HO, Knaub S. Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial. Critical Care 2002;Aug; 6(4):349-56. [MEDLINE: 12225612]
85. Wetterslev 2007 Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analyses may establish when firm evidence is reached in cumulative meta-analyses. Journal of Clinical Epidemiology 2007. [: DOI: 10.1016/j.jclinepi.2007.03.013]
86. Wiedermann 2002 Wiedermann CJ, Römisch J. The anti-inflammatory actions of antithrombin - a review. Acta Medica Austriaca 2002;29(3):89-92. [MEDLINE: 12168569]
87. Wiedermann 2004 Wiedermann CJ, Kaneider NC. Comparison of mechanisms after post-hoc analyses of the drotrecogin alfa (activated) and antithrombin III trials in severe sepsis. Annals of Medicine 2004;36:194-203. [MEDLINE: 15181975]
88. Afahari 2007 Afahari A, Wetterslev J, Brok J, Møller A. Antithrombin III in critically ill patients: systematic review with meta-analysis and trial sequential analysis. BMJ 2007;335(7632): 1248-51.